Eightsix Science is an applied neuroscience startup developing biohybrid neural graft technology for progressive brain replacement and cognitive preservation. Founded in 2024 by neuroengineer Daniel Burger, the company is headquartered in London and incubated at UtrechtInc, with team members drawn from EPFL, ETH Zurich, King's College London, and the Blue Brain Project.

The company's core approach, termed Ectopic Cognitive Preservation (ECP), involves the progressive, piecemeal substitution of aging or damaged brain tissue with biohybrid neural grafts. These grafts combine living neural tissue, potentially derived from patient-specific induced pluripotent stem cells, with micro- and nano-scale electronic components through 4D bioprinting. The goal is to maintain functional cognitive continuity throughout the replacement process via high-bandwidth brain-machine interfaces integrated into each graft.

Eightsix Science operates at the intersection of neural tissue engineering, brain-computer interfaces, and synthetic consciousness research. The company's long-term vision includes achieving biological independence of cognition from its original biological substrate. Eightsix secured pre-seed funding led by Tim Draper and is building its team across neurosurgery, tissue engineering, ethics, and in vivo research, with advisors from Cambridge University and the University of Tokyo.